|
|||||
|
|
Lithium therapy and cerebrospinal fluid biomarker levels in Alzheimer's disease |
|
| Authors: | Masahiro Maruyama Kota Ishizawa Naoki Tomita Miyako Nemoto Hiroyasu Yasuda Satoru Ebihara Takashi Ohrui Takashi Seki Koh Iwasaki Nobuyuki Okamura Makoto Higuchi Hiroshi Yoshida Yukitsuka Kudo Hiroyuki Arai Hidetada Sasaki |
| Affiliation: | Departments of Geriatric and Respiratory Medicine,;Pharmacology, and;Biomedical Engineering Research Organization, Tohoku University Graduate School of Medicine, and;Department of Geriatric and Complementary Medicine, Center for Asian Traditional Medicine Research, Sendai,;Laboratory for Proteolytic Neuroscience, RIKEN Brain Science Institute, Wako-shi, Saitama and;Research and Development Laboratory, Nipro Corporation, Shiga, Japan |
| Abstract: | Recent studies suggest that lithium may retard pathological deterioration by inhibiting aberrant phosphorylation of tau in Alzheimer's disease (AD). Here, we describe three cases of AD who were treated with lithium for agitation. However, there was no obvious improvement either in global cognition, agitation or cerebrospinal fluid markers that were thought to reflect Alzheimer's pathology. Increased dosages of lithium were not tolerated by the patients because of adverse effects. It is likely that AD patients do not benefit from lithium therapy as an alternative choice of treatment. |
| Keywords: | Alzheimer's disease beta amyloid 1–42 tau |